MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Xenon Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

33.26 0.82

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

33.2

Максимум

33.49

Ключови измерители

By Trading Economics

Приходи

638K

-65M

Продажби

7.5M

7.5M

EPS

-0.83

Марж на печалбата

-867.293

Служители

316

EBITDA

4.1M

-73M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+66.36% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-344M

2.4B

Предишно отваряне

32.44

Предишно затваряне

33.26

Настроения в новините

By Acuity

68%

32%

334 / 375 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.07.2025 г., 04:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

4.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

4.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

4.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

4.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

4.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

4.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

4.07.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

4.07.2025 г., 15:57 ч. UTC

Пазарно говорене

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4.07.2025 г., 15:49 ч. UTC

Пазарно говорене

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4.07.2025 г., 15:49 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4.07.2025 г., 15:49 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4.07.2025 г., 15:49 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole Received All Required Authorizations

4.07.2025 г., 15:48 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4.07.2025 г., 15:47 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole: Agreement Was Announced on Dec. 19

4.07.2025 г., 15:47 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4.07.2025 г., 15:46 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4.07.2025 г., 14:30 ч. UTC

Придобивния, сливания и поглъщания

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4.07.2025 г., 13:53 ч. UTC

Пазарно говорене

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4.07.2025 г., 13:41 ч. UTC

Пазарно говорене

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4.07.2025 г., 13:41 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

4.07.2025 г., 13:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

4.07.2025 г., 12:37 ч. UTC

Пазарно говорене

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4.07.2025 г., 12:37 ч. UTC

Пазарно говорене

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4.07.2025 г., 12:30 ч. UTC

Пазарно говорене

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4.07.2025 г., 12:15 ч. UTC

Пазарно говорене

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4.07.2025 г., 12:13 ч. UTC

Пазарно говорене

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4.07.2025 г., 12:02 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

66.36% нагоре

12-месечна прогноза

Среден 55.33 USD  66.36%

Висок 65 USD

Нисък 47 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

15 ratings

15

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

334 / 375 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.